ImmunoPET in Multiple Myeloma—What? So What? Now What?

Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (includi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Bailly, Clément, Chalopin, Benjamin, Gouard, Sébastien, Carlier, Thomas, Remaud-Le Saëc, Patricia, Marionneau-Lambot, Séverine, Moreau, Philippe, Touzeau, Cyrille, Kraeber-Bodere, Françoise, Bodet-Milin, Caroline, Chérel, Michel
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2020
Matèries:
Perspective
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7352991/
https://ncbi.nlm.nih.gov/pubmed/32512883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061467
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars